MS CAR t trial pulled before it even started
NCT ID NCT07364487
First seen Feb 02, 2026 · Last updated May 06, 2026 · Updated 9 times
Summary
This early-stage study aimed to test the safety of a new treatment called GC012F for people with multiple sclerosis. The treatment uses specially engineered immune cells (CAR T cells) to target the disease. However, the study was withdrawn before enrolling any participants, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Huashan Hospital Affiliated to Fudan University
Shanghai, Shanghai Municipality, 200040, China
Conditions
Explore the condition pages connected to this study.